Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients

Circulation Journal

Volumn 76, Issue 1, 2012, Pages 221-229

  Nohara, Ryuji ^a   Daida, Hiroyuki ^b   Hata, Mitsumasa ^c   Kaku, Kohei ^d   Kawamori, Ryuzo ^e   Kishimoto, Junji ^f   Kurabayashi, Masahiko ^g   Masuda, Izuru ^h   Sakuma, Ichiro ⁱ   Yamazaki, Tsutomu ^j   Yokoi, Hiroyoshi ^k   Yoshida, Masayuki ^l  

^a Kitano Hospital   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KYUSHU UNIVERSITY HOSPITAL   (Japan)

^g GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h Department of Internal Medicine Higashiyama Takeda Hospital ^*  (Japan)

ⁱ Hokko Memorial Clinic Caress Sapporo   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k KOKURA MEMORIAL HOSPITAL   (Japan)

^l TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

more..

Author keywords

Carotid intima media thickness; Dyslipidemia; Randomized controlled trial; Rosuvastatin; Statins

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTHRALGIA; ARTICLE; ATHEROSCLEROSIS; BACKACHE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSMYOTONIA; FEMALE; HEART INFARCTION; HEAVINESS; HEMATURIA; HUMAN; HYPERCHOLESTEROLEMIA; JAPANESE; KIDNEY FAILURE; LACUNAR STROKE; LIMB PAIN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL STIFFNESS; MYALGIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; SUPRAVENTRICULAR TACHYCARDIA; TENDINITIS; THALAMIC HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE PROGRESSION; FEMALE; FLUOROBENZENES; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES; PYRIMIDINES; SINGLE-BLIND METHOD; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84255172397     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0887     Document Type: Article

References (29)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
4. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
5. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
6. National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
7. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
8. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31: 811-822.
9. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50.
10. von Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (12 months) follow-up intravascular ultrasound. Circulation 2003; 108: 2757-2762.
11. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
12. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006; 295: 1556-1565.
13. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508.
14. Espeland MA, O'leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005; 6: 3.
15. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010; 122: e584-e636.
16. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA 2007; 297: 1344-1353.
17. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: Multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009; 73: 2110-2117.
18. Kurabayashi M, Sakuma I, Kawamori R, Daida H, Yamazaki T, Yoshida M, et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients? Rationale and design of the JART study. J Atheroscler Thromb 2010; 17: 416-422.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Joint committee with the guidelines subcommittee of the Japan Academy of Neurosonology for ultrasonic assessment of carotid artery disease and the subcommittee for research into methods of screening atherosclerotic lesions. Guidelines for ultrasonic assessment of carotid artery disease: Preliminary report. Neurosonology 2002; 15: 20-33.
21. Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T, et al. Evaluation of a new carotid intima-media thickness measurement by B-Mode ultrasonography using an innovative measurement software, Intimascope. Am J Hypertens 2006; 19: 1206-1212.
22. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline: Statistical principles for clinical trials. February 1998. http://www.ich.org/products/guidelines.html (accessed June 1, 2011).
23. Riccoioni G, Bassano LA, Bucciarelli T, Mancini B, di Ilio E D'Orazio N. Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: The Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study. Expert Opin Pharmacother 2008; 9: 2403-2408.
24. Soeda T, Uemura S, Okayama S, Kawasaki R, Sugawara Y, Nakagawa H, et al. Intensive lipid-lowering therapy with rosuvastatin stabilizes lipid-rich coronary plaques: Evaluation using dual-source computed tomography. Circ J 2011; 75: 2621-2627.
25. Saku K, Zhang B, Noda K on behalf of the PATROL Trial Investigators. Randamized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastation for safety and efficacy (quantity and quality of LDL): The PATROL trial. Circ J 2011; 75: 1493-1505.
26. Imano H, Noda H, Kitamura A, Sato S, Kiyama M, Sankai T, et al. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: The Circulatory Risk in Communities Study (CIRCS). Prev Med 2011; 52: 381-386.
27. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146: 483-494.
28. Kablak-Ziembicka A, Tracz W, Przewlocki T, Pieniazek P, Sokolowski A, Konieczynska M. Association of increased carotid intima-media thickness with the extent of coronary artery disease. Heart 2004; 90: 1286-1290.
29. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.